Contents 3 min read

Claim and source comparison

Modafinil: cognitive outcomes in healthy participants, US labeling and safety notices on pregnancy and contraception.

· Bounded source comparison; not a complete clinical review or independent medical endorsement.

Systematic review / meta-analysis

In the 2015 Battleday and Brem review, outcomes varied by task in healthy people without sleep deprivation. Some complex tests improved, while basic attention and memory results were mixed.

Differences in tasks and methods limit conclusions about general or long-term cognitive benefit and the safety of unsupervised use.

Source 1 · Abstract read

Official safety summary

The US PROVIGIL label lists adult indications for wakefulness in specific sleep disorders and warnings about serious rash, hypersensitivity and psychiatric symptoms.

These indications apply to the US product. Modafinil does not treat airway obstruction in sleep apnea, and the label provides no indication for cognitive use in healthy people.

Source 5 · Official summary read

Official safety summary

Modafinil can reduce the effectiveness of steroidal contraception during treatment. The US PROVIGIL label specifies 1 month of precautions after stopping, and the UK MHRA notice specifies 2 months. The MHRA advises against use during pregnancy.

These durations come from different national documents. Local product information and professional assessment guide the choice of method for each patient.

Source 5 · Source 6 · Official summary read

Our evidence and source methodology

modafinil: conceptual editorial illustration
Conceptual editorial artwork; not a research finding or evidence of clinical benefit in humans.

⚠ Medication Requiring a Prescription

The US PROVIGIL product information describes modafinil as a controlled prescription medicine. For a specific product in Türkiye, verify authorization, prescribing conditions and approved indications in current TİTCK records and product information. This general explanation does not determine the legal status of nonprescription sales or personal use.

What is Modafinil?

Modafinil is a prescription wakefulness-promoting drug approved in the United States in 1998. The US PROVIGIL label covers excessive sleepiness associated with narcolepsy, obstructive sleep apnea or shift work disorder in adults. It does not treat the underlying airway obstruction in sleep apnea.

Modafinil is a prescription wakefulness medicine for excessive sleepiness associated with specified sleep disorders. It does not replace sleep; cognitive benefits in healthy people vary by task and baseline condition and do not guarantee superior performance across all domains.

Mechanism of Effect

modafinil: conceptual editorial illustration
Conceptual editorial artwork; not a research finding or evidence of clinical benefit in humans. This schematic mechanism illustration does not establish clinical benefit in humans, a receptor reset or a safe dosing schedule.

The US PROVIGIL label states that the full mechanism promoting wakefulness is unknown. Dopamine-transporter binding and reuptake inhibition have been demonstrated; experimental findings involving other circuits are not established cognitive outcomes in humans.

Most mechanism findings in this section come from cell or animal experiments; they do not establish the same effects or clinical benefits in humans.

Clinical Evidence

Battleday and Brem (2015) published a systematic review of 24 studies in healthy, non-sleep-deprived people; it was not a quantitative meta-analysis. Some learning and complex-task measures improved, while simple-task findings were mixed. These results do not establish general or long-term cognitive superiority or a safe self-use protocol in healthy people.

Modafinil carries a risk of misuse. The US PROVIGIL label classifies it as a Schedule IV controlled substance and reports euphoric/stimulant effects in humans. Different pharmacology does not mean protection from dependence or safety of unsupervised use.

Dose information and research limits

Dose information and research limits

This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.

Safety and Side Effects

Modafinil does not replace sleep and should follow the prescriber’s plan. No validated “two or three days a week” nootropic cycle exists. The PROVIGIL label warns about serious rash/Stevens–Johnson syndrome, angioedema, psychiatric symptoms and cardiovascular events. New rash, chest pain or psychosis/mania symptoms require stopping the medicine and immediate medical assessment.

Modafinil can reduce the effectiveness of steroidal contraception during treatment. The US PROVIGIL label specifies 1 month of precautions after stopping, and the UK MHRA notice specifies 2 months. The MHRA advises against use during pregnancy.

Related research and reading

These links show explicit editorial topic connections; they do not confirm a mechanism, efficacy or the safety of combined use. News dates refer to the source or event.

Educational guides

  • Nootropic Cycling: Evidence and Limits

    Tolerance, dependence and withdrawal are different phenomena. Breaks may be considered for some substances, but there is no validated cycling schedule for all nootropics.

Sources

  1. Battleday RM, Brem AK. (2015). Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review. European Neuropsychopharmacology, 25(11), 1865–1881. PubMed · PMID 26381811
  2. Minzenberg MJ, Carter CS. (2008). Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology, 33(7), 1477–1502. PubMed · PMID 17712350
  3. Müller U, et al. (2013). Effects of modafinil on non-verbal cognition, task enjoyment and creative thinking in healthy volunteers. Neuropharmacology, 64(5), 490–495. PubMed · PMID 22820554
  4. Volkow ND, et al. (2009). Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA, 301(11), 1148–1154. PubMed · PMID 19293415
  5. US National Library of Medicine. PROVIGIL (modafinil): Prescribing Information and Medication Guide. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e16c26ad-7bc2-d155-3a5d-da83ad6492c8 US National Library of Medicine · DailyMed
  6. Medicines and Healthcare products Regulatory Agency. (2020). Modafinil (Provigil): increased risk of congenital malformations if used during pregnancy. https://www.gov.uk/drug-safety-update/modafinil-provigil-increased-risk-of-congenital-malformations-if-used-during-pregnancy Medicines and Healthcare products Regulatory Agency

Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory

Frequently Asked Questions